Dee E. Silver

816 total citations
23 papers, 604 citations indexed

About

Dee E. Silver is a scholar working on Neurology, Cognitive Neuroscience and Organic Chemistry. According to data from OpenAlex, Dee E. Silver has authored 23 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Neurology, 10 papers in Cognitive Neuroscience and 2 papers in Organic Chemistry. Recurrent topics in Dee E. Silver's work include Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (17 papers) and Autism Spectrum Disorder Research (10 papers). Dee E. Silver is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (17 papers) and Autism Spectrum Disorder Research (10 papers). Dee E. Silver collaborates with scholars based in United States, Ukraine and Spain. Dee E. Silver's co-authors include Mark Stacy, William C. Koller, A. L. Sahs, Tilak Mendis, Philip Chaikin, James P. Sutton, Akihisa Mori, N. M. Sussman, Abraham Lieberman and Stuart Isaacson and has published in prestigious journals such as Neurology, Movement Disorders and Journal of Neural Transmission.

In The Last Decade

Dee E. Silver

23 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dee E. Silver United States 14 491 165 85 82 62 23 604
Robert Altman Canada 3 258 0.5× 52 0.3× 44 0.5× 53 0.6× 85 1.4× 6 353
Dieter Volc Austria 10 313 0.6× 132 0.8× 23 0.3× 96 1.2× 94 1.5× 17 534
Brandon Barton United States 8 662 1.3× 231 1.4× 11 0.1× 111 1.4× 54 0.9× 17 818
Th. M�ller Germany 9 232 0.5× 90 0.5× 15 0.2× 79 1.0× 29 0.5× 10 348
Chandrashekhar Meshram India 6 353 0.7× 123 0.7× 6 0.1× 63 0.8× 39 0.6× 8 420
M. Rodriguez Spain 10 478 1.0× 280 1.7× 10 0.1× 68 0.8× 17 0.3× 17 672
Ariane Park United States 7 252 0.5× 71 0.4× 22 0.3× 62 0.8× 44 0.7× 8 379
Mubasher A. Qamar United Kingdom 11 339 0.7× 87 0.5× 6 0.1× 69 0.8× 71 1.1× 24 409
József Attila Szász Romania 13 642 1.3× 134 0.8× 6 0.1× 91 1.1× 215 3.5× 38 751
Helena Nissinen Finland 6 434 0.9× 99 0.6× 6 0.1× 74 0.9× 63 1.0× 6 500

Countries citing papers authored by Dee E. Silver

Since Specialization
Citations

This map shows the geographic impact of Dee E. Silver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dee E. Silver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dee E. Silver more than expected).

Fields of papers citing papers by Dee E. Silver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dee E. Silver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dee E. Silver. The network helps show where Dee E. Silver may publish in the future.

Co-authorship network of co-authors of Dee E. Silver

This figure shows the co-authorship network connecting the top 25 collaborators of Dee E. Silver. A scholar is included among the top collaborators of Dee E. Silver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dee E. Silver. Dee E. Silver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Espay, Alberto J., Fernando Pagán, Benjamin L. Walter, et al.. (2017). Optimizing extended-release carbidopa/levodopa in Parkinson disease. Neurology Clinical Practice. 7(1). 86–93. 15 indexed citations
2.
Silver, Dee E. & Richard Trosch. (2016). Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease. Neurology. 86(14_supplement_1). S25–35. 3 indexed citations
3.
Elmer, Lawrence, Dee E. Silver, Ann Hsu, et al.. (2015). Comparison of efficacy from phase 3 clinical trials of IPX066, an extended-release carbidopa-levodopa formulation, in Parkinson’s disease (P1.191). Neurology. 84(14_supplement). 1 indexed citations
4.
Waters, Cheryl, Paul A. Nausieda, Monika Rudzińska, et al.. (2015). Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial. CNS Drugs. 29(4). 341–350. 27 indexed citations
5.
Hauser, Robert A., et al.. (2014). Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease. Movement Disorders. 29(8). 1028–1034. 47 indexed citations
6.
Silver, Dee E. & Philip O. Buck. (2011). Determining the Efficacy of Rasagiline in Reducing Bradykinesia Among Parkinson's Disease Patients: A Review. International Journal of Neuroscience. 121(9). 485–489. 2 indexed citations
7.
Seeberger, Lauren, et al.. (2011). Rasagiline. The Neurologist. 17(6). 318–324. 7 indexed citations
8.
Lyons, Kelly E., Joseph H. Friedman, Neal Hermanowicz, et al.. (2010). Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects. Clinical Neuropharmacology. 33(1). 5–10. 31 indexed citations
9.
Ondo, William G., Christine Hunter, Stuart Isaacson, et al.. (2010). Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson’s disease. Parkinsonism & Related Disorders. 17(2). 117–118. 10 indexed citations
10.
Baker, William L., et al.. (2008). Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis. Parkinsonism & Related Disorders. 15(4). 287–294. 53 indexed citations
11.
Silver, Dee E.. (2008). Early, Nondisabling Parkinson's Disease: Weighing the Options for Initial Therapy. Neurologic Clinics. 26(3). 1–13. 3 indexed citations
12.
Trosch, Richard, Dee E. Silver, & Peter B. Bottini. (2008). Intermittent Subcutaneous Apomorphine Therapy for ???Off??? Episodes in Parkinson??s Disease. CNS Drugs. 22(6). 519–527. 22 indexed citations
13.
Stacy, Mark & Dee E. Silver. (2007). Apomorphine for the acute treatment of “off” episodes in Parkinson's disease. Parkinsonism & Related Disorders. 14(2). 85–92. 36 indexed citations
14.
Silver, Dee E.. (2006). Impact of Functional Age on the Use of Dopamine Agonists in Patients With Parkinson Disease. The Neurologist. 12(4). 214–223. 14 indexed citations
15.
Koller, William C., et al.. (2004). An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off. Journal of Neural Transmission. 112(2). 221–230. 37 indexed citations
16.
Silver, Dee E.. (2004). Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Review of Neurotherapeutics. 4(4). 589–599. 15 indexed citations
17.
Silver, Dee E. & Stefano Ruggieri. (1998). Initiating therapy for Parkinson's disease. Neurology. 50(6_suppl_6). S18–22; discussion S44. 14 indexed citations
18.
Silver, Dee E., et al.. (1975). Amantadine in Parkinson's disease. Neurology. 25(7). 603–603. 43 indexed citations
19.
Silver, Dee E. & A. L. Sahs. (1972). Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride. Neurology. 22(7). 665–665. 13 indexed citations
20.
Silver, Dee E. & A. L. Sahs. (1971). Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.. PubMed. 96. 307–8. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Altman Breakdown of academic impact, for papers by Dieter Volc Breakdown of academic impact, for papers by Brandon Barton Breakdown of academic impact, for papers by Th. M�ller Breakdown of academic impact, for papers by Chandrashekhar Meshram Breakdown of academic impact, for papers by M. Rodriguez Breakdown of academic impact, for papers by Ariane Park Breakdown of academic impact, for papers by Mubasher A. Qamar Breakdown of academic impact, for papers by József Attila Szász Breakdown of academic impact, for papers by Helena Nissinen
Rankless by CCL
2026